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We present preliminary clinical experience with combined consideration of the commonly used BMI (body mass index) and the
newly developed ABSI (a body shape index) using a point of care anthropometric calculator for comparisons of index values
and associated relative risks to population normals. In a series of 282 patients, BMI and ABSI were close to being independently
distributed, supporting the value of considering both indices. Three selected cases illustrate scenarios where assessment of ABSI
together with BMI could inform patient care and counseling. These data suggest that combined assessment of BMI and ABSI may
prove useful in clinical practice.

1. Introduction
Quantities derived from simple body measurements (anthropometrics), most commonly body mass index (BMI), have
been extensively applied in population level risk assessment
in recent years [1]. Despite the introduction of multiple new
biochemical and genomic tests, the availability and low cost
of height, weight, and waist circumference measurements
will likely continue to be of interest for epidemiologic and
clinical risk assessment. BMI was derived more than a
century ago by Adolphe Quetelet to express body weight
(𝑊) independently of height (𝐻) as BMI = 𝑊 ⋅ 𝐻−2 and
relates to the historical discipline of allometry, with its focus
on power-law scaling of biological quantities [2]. Concern
regarding the appropriateness of health assessment based on
BMI guidelines has arisen with recognition of the “obesity
paradox,” perhaps better designated the “BMI paradox” [3]:
a large cardiovascular and general medical and surgical
literature finds the risk for adverse outcomes in many cohorts
is actually lower for people whose BMI is modestly elevated
(25–35, Overweight to Obesity I using World Health Organization (WHO) BMI range definitions [4, 5]) compared to
people with WHO Normal BMI of 18.5–25.
The relationship of abdominal obesity to cardiovascular
risk is well established. More specifically, there is evidence

that metabolic risk correlates with the extent of visceral
obesity, while subcutaneous fat is actually a source of protective adipokines. However, partitioning of abdominal obesity
requires imaging technology not available to clinicians. The
measurement of waist circumference (WC) has become the
predominant indicator of abdominal obesity and associated
visceral obesity, and WC cutoffs are suggested by national
and international health organizations to supplement BMI
for obesity assessment [5]. In fact, WC is strongly predictive
of cardiovascular risk. However, there is a very high simple
correlation between BMI and WC of 𝑟 ≈ 0.7–0.9 [3, 5, 6].
Efforts to better isolate abnormal abdominal shape apart
from BMI have included WC to hip circumference ratio
and height to WC ratio. These demonstrate lower but still
clinically important correlations with BMI, 0.4–0.5 [7]. Using
these indices in conjunction with BMI to better assess risk is
complicated by their correlations with BMI.
Several years ago, to address the above concerns, we
introduced a body shape index (ABSI) based on an allometric
power-law relationship between WC and BMI. ABSI was
derived empirically from the National Health and Nutrition
Examination Survey (NHANES) 1999–2004, a population
sample of the United States [6]. The resulting ABSI was, as
intended, almost independent of BMI, both for NHANES
and, with minor adjustments, for studies from a number of
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other geographic regions [7, 8]. Further, we analyzed mortality follow-up data from NHANES and from a British study. In
both, ABSI showed a direct association with mortality, with
near log-linear risk increase, especially over the higher range
of ABSI [6, 7]. Based on results from Cox proportional hazard
modeling for mortality risk and Akaike information criterion
score differences, we showed for these cohorts that ABSI
predicted mortality better than BMI, WC, or waist/height and
waist/hip ratios [7].
There are now dozens of studies that have evaluated the
correlation of ABSI with various health-related measures
and outcomes. We have previously listed and commented
on some of them [1]. Relative risk (RR) estimates for ABSI
have generally been similar in magnitude to those which can
be made using BMI and other simple biometrics. In these
studies, when significant, RRs are often modest, around 1.1–
1.2 per standard deviation change in each indicator, and the
RRs for different indicators are statistically similar to each
other [9, 10]. However, few of the studies published to date
exploited the statistical independence of BMI and ABSI to
obtain combined RR values and confidence intervals, which
we expect to be more informative than for the individual
anthropometrics.
Much recent clinical application of simple biometrics has
been based on combining BMI categories with WC cutoffs
in an attempt to highlight the added risk of abdominal and
visceral adiposity (corresponding to high WC). However,
we demonstrated the limitations of WC cutoffs for risk
stratification from national cohort data: WC cutoffs were
exceeded, for example, 93% of the time for Obesity I (BMI 30–
34.9) and 100% for Extreme Obesity (BMI > 40) individuals,
so that the WC cutoff had little discriminatory power in
these categories. On the other hand, ABSI was above average
approximately 50% of the time across the entire range of BMI
[1]. This motivates our hypothesis that adding ABSI to BMI
in assessment could be valuable for clinical purposes beyond
the prevailing BMI and WC cutoff-based categorizations,
since the statistical independence of the two measures allows
overall risk to be expressed more accurately as the product of
the RR for BMI and RR for ABSI. To motivate future more
definitive work, we present here preliminary results and case
studies based on a practitioner’s experience with point of care
anthropometrics.

2. Materials and Methods
The first author practices general endocrinology in a singlespecialty small group with an urban and suburban patient
base. The office has electronic medical records, with visit
documentation entered on a laptop taken into the exam
room. Patients are weighed without shoes in light clothing
on an electronic scale, and height is measured with a wallmounted stadiometer. Height is recorded to the nearest
1/10 inch and weight to the nearest 1/10 pound. Patients
have WC measured on a clinically selected basis. WC is
determined with a nonrigid tape measure to the nearest
1/4 inch at the level of the iliac crests by a medical assistant
following NIH guidelines [11].
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Basic demographic data and height, weight, and WC were
entered into an anthropometric calculator and the results
are used in the course of the patient visit for diagnostic and
educational purposes. Calculated quantities included ABSI,
BMI, their 𝑧 scores (number of standard deviations above or
below the population average, controlling for age and sex),
and RR relative to United States population means, including 95% confidence intervals for RR, as estimated from a
mortality follow-up for a nationally representative cohort [6].
The ABSI and BMI attributable RRs are nonlinear empirically
derived functions of the respective 𝑧 scores. The combined
RR is the product of the ABSI and BMI component RRs.
A free version of our anthropometric calculator is available
at https://nirkrakauer.net/sw/absi-calculator.html and can be
experimented with to demonstrate how ABSI and BMI 𝑧
scores and the estimated RRs and their confidence intervals
depend on the entered height, weight, WC, age, and sex.
Over a one-year period, biometrics were recorded and
analyzed for 291 patient visits. Nine patients had serial or
duplicate entries, for 282 first-time individual analyses. Out of
these, 3 selected cases are detailed below to illustrate scenarios
where assessment of ABSI together with BMI could inform
patient care and counseling.

3. Results
For the series of 282 patients, the average (±SD) age was 47 ±
15; 71% were female. The patient ethnicities were representative of our office practice, about 50% African American and
50% non-Hispanic White. The average BMI of the patients
series was 36 ± 9 (1.3 ± 1.6 for 𝑧 score, denoting the number of
standard deviations above or below the NHANES 1999–2004
normals). For ABSI, the corresponding values were 0.0788 ±
0.0056 (−0.4 ± 1.2 for 𝑧 score) (Table 1). The combined BMIABSI RR for mortality had higher standard deviation across
the population than either BMI or ABSI attributable risks
alone did (Table 1), suggesting that the combination enables
better risk discrimination than either indicator used alone.
Male patients had higher BMI 𝑧 scores, but lower ABSI 𝑧
scores, than females.
As expected from previous studies, there was relatively
little correlation between ABSI and BMI, although it was
statistically significantly different from zero (𝑟 = −0.21 using
the raw values, −0.32 for the 𝑧 scores; 𝑝 < 0.001 for both).
As Table 2 shows, the minority of patients presenting with
below-average BMI (𝑧 < 0), who would thus be considered at
low risk under the WHO obesity guidelines, were in fact just
as likely to have above-average ABSI (𝑧 > 0), highlighting the
potential of ABSI to identify patients at metabolic risk who
may be missed by categorizations that are based primarily on
BMI.
Three selected patient cases demonstrate the potential
value of combined consideration of BMI and ABSI in the
clinical setting.
3.1. Case 1: Low BMI with Comparatively Higher ABSI—
Risk Reduction with Weight Regain and Stable WC. A 49year-old woman was referred with 22-year history of type
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Table 1: Anthropometric quantities and calculated relative risks means and standard deviations.

All
Women
Men

BMI
36.2 ± 9.4
35.0 ± 8.9
39.4 ± 9.9

ABSI
0.079 ± 0.006
0.078 ± 0.006
0.080 ± 0.005

𝑧-BMI
1.36 ± 1.59
0.99 ± 1.31
2.16 ± 1.89

Table 2: Contingency table for the distribution of patients with
above- versus below-average BMI and ABSI. The chi-square statistic
for this table is 1.02 (𝑝 = 0.31) indicating that above-average ABSI
and above-average BMI were not significantly correlated.
𝑧-ABSI > 0
𝑧-ABSI < 0

𝑧-BMI > 0
94 (33%)
146 (51%)

𝑧-ABSI < 0
23 (8%)
26 (9%)

2 diabetes mellitus. Maximum weight was 137 lbs 3 years
previously. She had involuntarily lost to 106 lbs (BMI of 19,
partly attributed to metformin diarrhea and terbinafine (for
onychomycosis great toe) induced diarrhea and dysgeusia).
Patient had retinopathy and years of no medical care or medication, which she attributed to being uninsured. Continuous
glucose monitoring showed both nocturnal hyperglycemia
and marked postprandial hyperglycemia. Biometrics showed
below-normal ABSI (below average risk) but significantly
elevated risk due to low BMI (based on the cohort data used
to construct the calculator, the lowest-risk BMI is in the high
normal to overweight range, with both lower and higher BMI
incurring elevated risk).
Oral agents were discontinued and basal insulin was
reinstituted, with subsequent addition of bolus insulin dosed
with a calculating glucometer (ACCU-CHEK Aviva Expert).
After three months, repeat anthropometrics showed weight
gain to BMI of 21, with WC of 26 inches compared to
27 inches at initial assessment. The calculated BMI-ABSI
combined RR decreased from above average (1.26) to just
better than average (0.91).
In clinical practice, the adverse prognosis associated with
low BMI may often be underappreciated. The decrease of risk
with improvement in underweight is seen for BMI (RR 1.65
decreasing to 1.26 or 24%). Less intuitively, the stable WC as
weight increased also reduced ABSI attributable risk (from
0.80 to 0.72 or 10%). Based on the statistical independence
of RR-BMI and RR-ABSI, the combined risk decreased from
1.34 to 0.91, or 32%, demonstrating the complementary use
of BMI and ABSI. The confidence intervals showed statistical
significance for all the RRs, except for the final combined
RR, which indicated now only average risk after the healthy
weight regain.
3.2. Case 2: Normal BMI with Elevated ABSI—Risk Reduction
by Relatively Greater Decrease in WC with Weight Loss. 26year-old woman was initially seen for postpartum hypothyroidism. Even with adequate thyroxine replacement and
exercise and dieting efforts, she found it very hard to lose

𝑧-ABSI
−0.35 ± 1.24
−0.26 ± 1.21
−0.58 ± 1.31

RR-BMI
1.17 ± 0.29
1.12 ± 0.24
1.30 ± 0.35

RR-ABSI
1.00 ± 0.35
1.03 ± 0.36
0.95 ± 0.32

RR-comb
1.16 ± 0.43
1.13 ± 0.43
1.21 ± 0.44

the 8 lb weight gained over prepregnancy. With normalrange BMI of 20 combined with relatively high WC of
33.75 inches (WHO cutoff is 34.6 inches for a woman), the
WHO classification does not identify her at increased risk.
However, her concerns were validated by a high ABSI and
elevated combined RR. On the presumption, supported by
the anthropometric risk indications, of a possible prediabetic
metabolic disorder, metformin was prescribed and lifestyle
measures redoubled. Repeat measurements after 5 months
showed 12 lb weight loss and reduction in combined RR to
significantly less than 1.
3.3. Case 3: Elevated BMI with Relatively Low ABSI—
Overall Average Risk. This is a case of 60-year-old woman
with lifelong weight struggles. Roux en Y bariatric surgery
was performed 13 years ago at 248 lbs. Hypertension did
not improve but is currently controlled on 5 medications.
Creatinine has been stable at ≈2 mg%. A recent course of
prednisone brought on 20 lbs weight gain. Anthropometrics
showed near-extreme obesity using WHO criteria but normal
combined RR thanks to relatively trim WC. Total body
DXA% fat was normal (𝑧 score of +0.3). The patient was
counseled that she not pursue aggressive medical weight
loss and rather emphasize general health maintenance. In
hindsight, although she was below her presurgical weight
at 213 lbs (−35 lbs or −14% initial body weight), one might
wonder how much she benefited health-wise from bariatric
surgery.
Assuming that she were today a candidate considering
bariatric surgery, her BMI of 39 and comorbid hypertension
would be in favor of surgical intervention. However, on
further assessment, her WC of 37 inches, while well above
the accepted cutoff value, corresponded to a remarkably low
ABSI 𝑧 score of −3.15 (more than 3 standard deviations
below the average value). One could therefore expect that
abdominal obesity contributes little to her cardiometabolic
risk. It is also notable that while the RR-BMI is elevated
(1.17), RR-ABSI is below average (0.68), as is the combined RR
(0.80). Based on the wide confidence intervals, all of which
include 1, none of these is significantly different from average
risk. Combined consideration of BMI-ABSI supported the
clinical judgment that aggressive attempts at weight loss
would not likely lead to better health outcome in this case.

4. Discussion
We presented experience with combination use of the
anthropometrics BMI and ABSI to illustrate the potential
advantages over BMI and WC cutoffs alone. The cases show
situations where the currently recommended calculation and
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discussion of BMI as the premier clinical obesity indicator
may result in an incomplete picture of a presenting patient’s
risk profile.
The measurement of WC beyond routine weight and
height was feasible in the medical office setting, with minimal
personnel training and equipment required. Dieticians and
exercise physiologists could also readily use this modality.
We see at least three clear clinical benefits of our BMIABSI risk calculator:
(1) On a population level, since ABSI quantifies body
shape (particularly abdominal adiposity) in a manner
that is independent of BMI (i.e., does not correlate
with BMI), the ABSI-BMI combination provides
better estimates of the relative risk of cardiometabolic
disease and mortality.
(2) Tracking changes in the relative risk over time from
the calculator should help provide a way to evaluate
the effectiveness of clinical interventions. Our finding
that changes in mortality risk over time track changes
in ABSI [7] supports this clinical application.
(3) The BMI-ABSI risk calculator may be used to guide
clinical decision-making and to assess comparative
effectiveness. For example, ABSI might be an additional predictor of the likelihood of health benefits
from bariatric surgery [12]. As another example, in the
setting of medical weight loss, high ABSI may indicate
a higher likelihood of response to metabolic versus
appetite suppressive agents. Appropriate studies could
verify the value of combined assessment of BMI and
ABSI for particular medical conditions and in specific
clinical settings, including hospital and managed care
systems.
There are a number of additional directions we are
exploring to make the risk calculations more useful, based
on analysis of more large cohort studies with appropriate follow-up data. These include correlating with risk of
metabolic syndrome and with conditions such as coronary
artery disease, cancer, and stroke as well as with mortality;
better understanding differences in risk associations across
ethnicities and nations; and adding information from other
body measures such as hip circumference to potentially
improve risk assessment further.

5. Conclusion
In an era of increasing sophistication and cost of medical care,
the simple measurements of height, weight, and waist circumference continue to have a role both for epidemiologists
and medical practitioners and in fact offer prognostic value
comparable to that of more expensive and invasive laboratory
tests [13]. The combination of BMI and ABSI appears to
outperform the now-routine use of BMI (or any other single
index), while still fitting into the clinical setting, where basic
measurements can be entered into calculators such as our
online one.
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